4-methylchroman | 16982-89-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 4-methylchroman
• 英文别名: 4-methylchromane；4-methyl-3,4-dihydro-2H-chromene
• CAS: 16982-89-1
• 化学式: C₁₀H₁₂O
• 分子量: 148.205
• InChiKey: LPQYIGNYKIDLEY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  二氯乙酰氯 、 4-methylchroman 在 aluminum (III) chloride 作用下， 以 二氯甲烷 为溶剂， 反应 0.17h， 生成 2,2-dichloro-1-(4-methyl-3,4-dihydro-2H-chromen-6-yl)ethanone
  参考文献：
  名称：

  靶向丙酮酸脱氢酶激酶1的二氯苯乙酮具有提高的选择性和抗增殖活性：合成与构效关系

  摘要：

  二氯苯乙酮是一种丙酮酸脱氢酶激酶1（PDK1）抑制剂，具有次优的激酶选择性。在这里，我们报告了一系列新型二氯苯乙酮的合成和生物学评估。结构-活性关系分析（SARS）使我们能够确定3个有效的化合物，即54，55，和64，其抑制PDK1功能，激活丙酮酸脱氢酶复合物，和降低的NCI-H1975细胞的增殖。线粒体生物能量学吸附测定法表明，54，55，和64增强的癌细胞中氧化磷酸化，这可能有助于所观察到的抗增殖作用。总的来说，这些结果表明：54，55，和64可以是有前途的化合物为有效的PDK1抑制剂的开发。

  DOI：

  10.1016/j.bmcl.2018.09.026
• 作为产物：
  描述：

  but-2-ynyloxybenzene 在 palladium diacetate 、 三氟乙酸 作用下， 反应 1.0h， 以10%的产率得到4-methylchroman
  参考文献：
  名称：

  Pt(IV)-catalyzed cyclization of arene–alkyne substrates via C–H bond functionalization

  摘要：

  We herein report that PtCl4 has proven to be a hydroarylation catalyst with an efficiency and substrate scope superior to previously known methods. This catalyst demonstrated consistent performance with arene-yne substrates of diverse structural features, including propargyl ethers, propargylamines, and alkynoate esters, providing good to excellent yields of the 6-endo products (chromenes, dihydroquinolines, and coumarins). In contrast, Pt(II), Pd(II), and Ga(III) salts were shown to be sensitive to the substitution on the alkyne moiety. PtCl4 is compatible with both terminal and disubstituted alkynes, as well as with various functionalities on the arene ring, including methyl, methoxyl, hydroxyl, protected amine, and halide. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2003.05.003

文献信息

• HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER
  申请人：Asana Biosciences, LLC

  公开号：US20160362407A1

  公开（公告）日：2016-12-15

  The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and R 1 to R 8 are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.

  本申请提供了新颖的杂环化合物及其药用可接受的盐。还提供了制备这些化合物的方法。这些化合物对抑制ERK1/2有用。通过向需要治疗的患者施用式(I)的一个或多个化合物的治疗有效量，其中X、Y、Z、J、M和R1至R8在此处定义，这些化合物在治疗与RAS/RAF/MEK/ERK通路失调相关的疾病方面是有效的。可以使用这些化合物治疗各种疾病，包括以异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症。
• [EN] SMALL MOLECULE MODULATORS OF IL-17<br/>[FR] MODULATEURS À PETITES MOLÉCULES D'IL-17
  申请人：LEO PHARMA AS

  公开号：WO2021250194A1

  公开（公告）日：2021-12-16

  The present invention relates to a compound according to formula (I), (I) and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

  本发明涉及一种符合式(I)的化合物，以及其药学上可接受的盐、水合物或溶剂合物。该发明还涉及上述化合物在治疗中的应用，包括包含该化合物的药物组合物，用于使用该化合物制造药物的方法，例如用于治疗皮肤病等疾病的方法。
• TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS
  申请人：Arvinas, Inc.

  公开号：US20180155322A1

  公开（公告）日：2018-06-07

  The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, Inhibitors of Apoptosis Proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，这些化合物可用作雌激素受体（目标蛋白）的调节剂。特别是，本公开涉及包含在一段至少有一种Von Hippel-Lindau配体、一种cereblon配体、凋亡抑制蛋白配体、小鼠双分钟同源2配体或其组合的双功能化合物，这些配体与相应的E3泛素连接酶结合，在另一端有一个与目标蛋白结合的部分，使得目标蛋白被置于泛素连接酶附近，以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白降解/抑制相关的广泛药理活性。可以通过本公开的化合物和组合物治疗或预防由目标蛋白聚集或积累引起的疾病或障碍。
• Radical Hydrodehalogenation of Aryl Bromides and Chlorides with Sodium Hydride and 1,4-Dioxane
  作者：Tobias Hokamp、Abhishek Dewanji、Maximilian Lübbesmeyer、Christian Mück-Lichtenfeld、Ernst-Ulrich Würthwein、Armido Studer

  DOI：10.1002/anie.201706534

  日期：2017.10.16

  It is the combo! NaH in combination with 1,4-dioxane serves as the reagent for the radical chain reduction of various aryl halides. Hydrodehalogenation is initiated by 1,10-phenanthroline (phen) at elevated temperature and can be combined with a typical radical cyclization reaction. the reactions proceed via electron catalysis.

  这是组合！NaH与1,4-二恶烷的组合用作各种芳基卤化物自由基链还原的试剂。加氢脱卤化反应是在高温下由1,10-菲咯啉（phen）引发的，可与典型的自由基环化反应结合使用。反应通过电子催化进行。
• [EN] RORγ MODULATORS<br/>[FR] MODULATEURS DE ROR&Ggr;
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015035278A1

  公开（公告）日：2015-03-12

  Described are RORγ modulators of the formula (I), or pharmaceutically acceptable salts thereof, wherein all substituents are defined herein. The invention includes stereoisomeric forms of the compounds of formula I, including stereoisomerically-pure, scalemic and racemic form, as well as tautomers thereof. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

  描述了公式（I）的RORγ调节剂，或其药学上可接受的盐，其中所有取代基在此处定义。该发明包括公式I化合物的立体异构体形式，包括立体异构纯、立体混合和消旋形式，以及其互变异构体。还提供了包含相同化合物的药物组合物。这些化合物和组合物在调节细胞中的RORγ活性的方法以及治疗患有疾病或紊乱的受试者的方法中是有用的，其中受试者在调节RORγ活性方面会从中获益，例如自身免疫和/或炎症性疾病。

表征谱图